Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review

References

• American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-V 5th ed.). Arlington: American Psychiatric Publishing; 2013.
   Google Scholar
• Hembree WC , Cohen-Kettenis P , Delemarre-van de Waal HA , et al . Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132–54.
   PubMed Web of Science ®Google Scholar
• Meriggiola MC , Jannini EA , Lenzi A , et al . Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol 2010;162:831–3.
   PubMed Web of Science ®Google Scholar
• Asscheman H , Giltay EJ , Megens JAJ , et al . A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635–42.
   PubMed Web of Science ®Google Scholar
• Cebula H , Pham TQ , Boyer P , et al . Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochir 2010;52:1955–6.
   Web of Science ®Google Scholar
• Gazzeri R , Galarza M , Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 2007;357:2411–12.
   PubMed Web of Science ®Google Scholar
• Deipolyi AR , Han SJ , Parsa AT. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. J Clin Neurosci 2010;17:1324–6.
   PubMed Web of Science ®Google Scholar
• Bergoglio MT , Gómez-Balaguer M , Almonacid Folch E , et al . Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinol Nutr 2012;60:264–7.
   PubMedGoogle Scholar
• ter Wengel PV , Martine E , Gooren L , et al . Meningiomas in three male-to-female transgenders subjects using oestrogens/progestogens and review of the literature. Andrologia 2016;48:1130–7.
   PubMed Web of Science ®Google Scholar
• Claus EB , Bondy ML , Schildkraut JM , et al . Epidemiology of intracranial meningioma. Neurosurgery 2005;57:1088–95.
   PubMed Web of Science ®Google Scholar
• Wrensch M , Minn Y , Chew T , et al . Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4:278–99.
   PubMed Web of Science ®Google Scholar
• Wigertz A , Lönn S , Hall P , et al . Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008;17:2663–70.
   PubMed Web of Science ®Google Scholar
• Hatiboglu MA , Cosar M , Iplikcioglu AC , et al . Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol 2008;69:356–62.
   PubMedGoogle Scholar
• Wigertz A , Lönn S , Mathiesen T , et al . Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006;164:629–36.
   PubMed Web of Science ®Google Scholar
• Blankenstein MA , Verheijen FM , Jacobs JM , et al . Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000;65:795–800.
   PubMed Web of Science ®Google Scholar
• Moss J , DeCastro R , Patronas NJ , et al . Meningiomas in lymphangioleiomyomatosis. JAMA 2001;286:1879–81.
   PubMed Web of Science ®Google Scholar
• Gonçalves AMG , Page P , Domigo V , et al . Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 2010;31:1504–5.
   PubMed Web of Science ®Google Scholar
• Shimizu J , Matsumoto M , Yamazaki E , et al . Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 2008;48:227–30.
   PubMed Web of Science ®Google Scholar
• Pozzati E , Zucchelli M , Schiavina M , et al . Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report. Surg Neurol 2007;68:671–4.
   PubMedGoogle Scholar
• Froelich S , Dali-Youcef N , Boyer P , et al . Does cyproterone acetate promote multiple meningiomas. Endocrine Abstract of the 10th European Congress of Endocrinology; 2008;16:158.
   Google Scholar
• Grunberg SM , Weiss MH , Russell CA , et al . Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727–33.
   PubMed Web of Science ®Google Scholar
• Pharmacovigilance Working Party (PhVWP) . Monthly report, November 2009. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Report/2009/12/WC500016972.pdf [last accessed 25 Jun 2011].
   Google Scholar
• Cea-Soriano L , Blenk T , Wallander MA , et al . Hormonal therapies and meningioma: is there a link? Cancer Epidemiol 2012;36:198–205.
   PubMed Web of Science ®Google Scholar
• Gil M , Oliva B , Timoner J , et al . Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 2011;72:965–8.
   PubMed Web of Science ®Google Scholar
• Gooren LJ , Giltay EJ , Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008;93:19–25.
   PubMed Web of Science ®Google Scholar
• Meriggiola MC , Gava G. Endocrine care of transpeople. Part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol 2015;83:607–15.
   PubMed Web of Science ®Google Scholar
• Gulmez SE , Lassen AT , Aalykke C. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008;66:294–9.
   PubMed Web of Science ®Google Scholar